Characterization of the Use and Efficacy of Isavuconazonium Sulfate in a Pediatric Oncology and Stem Cell Transplant Population: A Single Institution Retrospective Review-Reference-Cited by-同舟云学术

Characterization of the Use and Efficacy of Isavuconazonium Sulfate in a Pediatric Oncology and Stem Cell Transplant Population: A Single Institution Retrospective Review

Published:2024-01-17 Issue: Volume: Page:
ISSN:1077-4114
Container-title:Journal of Pediatric Hematology/Oncology
language:en
Short-container-title:

Author:

Kunvarjee Binni¹,Siver Molly¹,Mathew Sherry¹,Steiger Samantha¹,Lee Yeon Joo²,Spitzer Barbara³

Affiliation:

1. Department of Pharmacy

2. Department of Medicine, Infectious Diseases Service

3. Department of Pediatrics, Memorial Sloan Kettering Cancer Center, NY

Abstract

Isavuconazonium sulfate (ISA) is a triazole antifungal approved for the treatment of invasive aspergillosis and mucormycosis in adults. This single-center, retrospective review of pediatric oncology and stem cell transplant patients receiving ISA for prophylaxis (n=20) or treatment (n=6) of invasive fungal disease (IFD) aims to characterize real-world clinical efficacy and toxicity of ISA in patients <18 years of age. Of 20 patients receiving ISA for prophylaxis, three patients had presumed breakthrough IFD (1 proven, 2 probable/possible). No adverse effects were attributed to ISA use or led to the discontinuation of therapy.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Oncology,Hematology,Pediatrics, Perinatology and Child Health

Reference23 articles.

1. Classification of treatment-related mortality in children with cancer: a systematic assessment;Alexander;Lancet Oncol,2015

2. Clinical Practice Guideline for systemic antifungal prophylaxis in pediatric patients with cancer and hematopoietic stem-cell transplantation recipients;Lehrnbecher;J Clin Oncol,2020

3. 824 An Open-Label Phase 3 Study of Isavuconazole (VITAL): focus on mucormycosis;Marty;Open Forum Infect Dis,2014

4. Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): A phase 3, randomised-controlled, non-inferiority trial;Maertens;Lancet,2016

5. Revision and Update of the Consensus Definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium;Donnelly;Clin Infect Dis,2020